According to a post on the FDA’s website, Juno Therapeutics, a Bristol-Myers Squibb company, received orphan designation for its treatment of nodal marginal zone lymphoma, lisocabtagene maraleucel. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMY:
- Bristol-Myers announces three-year follow-up results from CheckMate-816 study
- Zevra Therapeutics appoints Dixon to board of directors
- Bristol-Myers announces european approval of Sotyktu
- Evotec, Bristol-Myers expand strategic neurodegeneration partnership
- BridgeBio announces first patient dosed in Phase 1 trial of BBP-398 with OPDIVO